SaniMed Science Group Founder Jim Wu Joins Bullpen Inviting You to Co-Build a New Platform for Cross-Border Healthcare Innovation

Jim Wu, Chairman of BioTech (Shanghai), Joins BullpenAppointed Lifetime Founder Member and Money Ball Program CoachConnecting the U.S.–China Healthcare Innovation Ecosystem to Advance Global Biopharma Investment and Collaboration

Recently, Jim Wu, M.D., MBA, Founder of SaniMed Science Group and Chairman of BioTech (Shanghai) Technology Co., Ltd., officially joined the Bullpen Club in the United States as a Lifetime Founder Member. He has also been invited to serve as a Coach in the Bullpen Money Ball Program, contributing to the international acceleration of global biotech and health technology ventures.

---

💼 About Bullpen Club

Bullpen is a global founder and investor community bringing together leaders in life sciences, medical devices, digital health, and AI-enabled healthcare. Its members include accomplished entrepreneurs, investors, and industry experts worldwide.

Guided by its core philosophy — “Find Someone to Help. Repeat.” — Bullpen is dedicated to connecting promising startups with capital and industry resources, accelerating the commercialization of breakthrough innovations.

---

⚾ About the Money Ball Program

Money Ball is Bullpen’s flagship incubation and investment acceleration program, focused on early-stage companies in life sciences and healthcare innovation. The program features two stages — Tryouts and Accelerate — offering selected startups access to top-tier mentorship, strategic partnerships, fundraising preparation, and Silicon Valley–style entrepreneurial resources.

Its global mentor network comprises industry leaders across biopharma, medical devices, and digital health, supporting founders in refining business models, strengthening investor presentations, and engaging with international capital markets.

---

👨‍⚕️ About Jim Wu, M.D., MBA

With nearly three decades of experience in the global healthcare industry, Jim Wu has deep expertise spanning medical devices, biopharmaceutical innovation, cross-border investment, regulatory strategy, and global market entry. He is an active leader within both U.S. and China healthcare innovation ecosystems.

He is the Founder of SaniMed Science Group, Co-Founder of TomoWave Medical Group, Chairman of BioTech (Shanghai) Technology Co., Ltd., and an Investment Partner at TomoWave (Suzhou) Medical Imaging. His long-term focus includes the commercialization and globalization of cutting-edge technologies such as photoacoustic imaging, chronic disease monitoring, and AI-driven diagnostics.

Jim Wu currently serves as a Lifetime Founder Member and Accelerator Mentor at Bullpen, as well as an Innovation & Entrepreneurship Mentor at the Lingang Medical Device Innovation Center (Shanghai), providing structured guidance to Chinese healthcare companies expanding internationally.

He is a Distinguished Alumnus and Alumni Advisor of Peking University Health Science Center, a member of the Leadership Committee of the PKU–University of Michigan Joint Institute, and a certificate holder of MIT’s “AI in Pharma & Biotech” program. He is also a Founding Core Member of the Founder Institute (HealthTech Track) and a member of InnovatorMD, actively advancing the integration of AI into biopharma and medical device development.

In addition, Jim Wu serves as President of the Global Health Interactive Foundation and Chairman of the Houston International Trade Development Council (HITDC), where he is committed to building long-term bridges between U.S. and China healthcare innovation, capital, and markets.

---

🌎 Looking Ahead

Following his appointment at Bullpen, Jim Wu will focus on facilitating deep connections between Chinese and Asian biotech companies and global investors, AI healthcare innovators, and multinational industry partners.

Through the planned “U.S.–China Healthcare Innovation Bridge Initiative,” he aims to help more Chinese innovative drug and medical device companies gain international visibility, access global capital, and participate in premier industry events such as JPM Week and the BIO International Convention, jointly exploring new opportunities in global healthcare innovation.

---